Document:

Exhibit 10.7

 

AMENDMENT TWO

To

LIMITED EXCLUSIVE

PATENT LICENSE AGREEMENT

 

For 

 

DIAGNOSTIC KIOSK

For Food Safety, Water Quality Monitoring, and

Human/Veterinary Clinical Diagnostics

 

Between

 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

 

and

 

BIONOMICS DIAGNOSTICS, INC.,

a wholly-owned subsidiary of LexaGene Holdings,
Inc.

 

LLNL Case No. TL02679.2

 

Lawrence Livermore National Laboratory

Innovation and Partnerships Office

P.O. Box 808, L-795, Livermore, CA 94551

 

August 4, 2017

 

     

     

    

 

	
    Bionomics Diagnostics, Inc., a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	
    Diagnostic Kiosk

    Amendment Two

 

AMENDMENT TWO

August 4, 2017

 

to

 

License Agreement - LLNL Case Number TL02679.0

for Diagnostic Kiosk

between Bionomics Diagnostics, Inc. and Lawrence
Livermore National Security, LLC

effective June 22, 2015

 

This Amendment Two to the License Agreement by and between Lawrence
Livermore National Security, LLC ("LLNS") and Bionomics Diagnostics, Inc. ("LICENSEE") is effective
as of the date of execution of this Amendment by the last signing Party. This Amendment and the associated License Agreement are subject
to overriding obligations to the Federal Government pursuant to the provisions of LLNS's Contract No DE-AC52-07NA27344 with the United
States Department of Energy ("DOE") for the operation of the Lawrence Livermore National Laboratory ("LLNL").

 

This Amendment Two will update Exhibit A (LICENSED PATENTS), to remove
IL11778B; and Exhibit B (RIGHTS GRANTED AN PERFORMANCE OBLIGATIONS), to modify the Performance Obligations. All other terms and conditions
remain the same.

 

Therefore, in consideration of the mutual covenants and obligations
recited herein, LLNS and LICENSEE hereby amend the License Agreement as follows:

 

	1.	Exhibit A (LICENSED PATENTS)

 

Delete Exhibit A in its entirety and replace with the following:

 

    	17GM0804	1	 TL02679.2
Amendment Two

     

    

 

	
    Bionomics Diagnostics, Inc., a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	
    Diagnostic Kiosk

    Amendment Two

 

EXHIBIT A- LICENSED PATENTS

 

The Licensed Patents are as follows:

 

UNITED STATES PATENTS:

 

	Invention Disclosure Number	Patent Number	Title	Inventors	Issue Date
	IL11778A	8,298,763	Automated High-Throughput Flow-Through Real-Time Diagnostic System	John Frederick Regan	10/30/12
	IL11901A	8,828,716	Disposable and Removable Nucleic Acid Extraction and Purification Cartridges for Automated Flow-Through Systems	John Frederick Regan	9/9/14

 

    	17GM0804	2	 TL02679.2
Amendment Two

     

    

 

	
    Bionomics Diagnostics, Inc., a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	
    Diagnostic Kiosk

    Amendment Two 

 

		2.
	Exhibit B (RIGHTS GRANTED
                                            AN PERFORMANCE OBLIGATIONS), Paragraph B.5 (Performance Obligations)

 

Delete Paragraph B.5 in its entirety and replace with the following:

 

B.5          Performance Obligations

 

B.5.1       LICENSEE will
complete proof-of-concept prototype by January 31, 2018.

 

		B.5.2	LICENSEE will achieve First Commercial Sale ("FCS") in the United States by June 30, 2019.

 

		B.5.3	LICENSEE will achieve FDA clearance to enter the food safety and veterinary diagnostics markets in the United States by September
31, 2019.

 

		B.5.4	LICENSEE will achieve cumulative sales of more than Ten Million Dollars ($10,000,000) within three (3) years of FCS.

 

		B.5.5	LICENSEE will achieve FDA clearance to perform human clinical diagnostics in the United States by December 31, 2021.

 

		B.5.6	The sales requirements specified above may , by mutual written consent of LICENSEE and LLNS, be amended and/or extended at
the written request of LICENSEE to LLNS, based upon legitimate business reasons specified in reasonable detail in such written
request.

 

		B.5.7	The first progress report will be due on February 28, 2016.

 

		B.5.8	LICENSEE will diligently proceed to commercially develop, file relevant regulatory applications for, and attempt to obtain
relevant regulatory commercialization approvals with respect to the manufacturing, marketing, and sale of Licensed Products.

 

    	17GM0804	3	 TL02679.2
Amendment Two

     

    

 

	
    Bionomics Diagnostics, Inc., a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	
    Diagnostic Kiosk

    Amendment Two 

 

LLNS and LICENSEE execute this Amendment, in duplicate originals,
by their respective officers who are duly authorized on the day and year that is written.

 

	BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc	 	LAWRENCE LIVERMORE NATIONAL SECURITY, LLC LAWRENCE LIVERMORE NATIONAL LABORATORY
	 	 	 
	By:	/s/ Jack Regan	 	By:	/s/ Richard Rankin
	Name:	Jack Regan	 	Name:	Richard A. Rankin
	Title:	CEO	 	Title:	Director, Innovation and Partnerships Office
	Date Signed:	08/04/2017	 	Date Signed:	08/08/2017

 

    	17GM0804	4	 TL02679.2
Amendment TwoExhibit 10.8

 

AMENDMENT THREE

To

LIMITED EXCLUSIVE

PATENT LICENSE AGREEMENT

 

For

 

DIAGNOSTIC KIOSK

For Food Safety, Water Quality Monitoring, and

Human/Veterinary Clinical Diagnostics

 

Between

 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

 

and

 

BIONOMICS DIAGNOSTICS, INC.,

a wholly-owned subsidiary of LexaGene Holdings, Inc.

 

LLNL Case No. TL02679.3

 

Lawrence Livermore National Laboratory

Innovation and Partnerships Office

P.O. Box 808, L-795, Livermore, CA 94551

 

September 14, 2017

 

     

     

    

 

	Bionomics Diagnostics, Inc.,
    a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	Diagnostic
    Kiosk

    Amendment
    Three

 

AMENDMENT THREE

September 14, 2017

 

to

 

License Agreement - LLNL Case Number TL02679.0

for Diagnostic Kiosk

between Bionomics Diagnostics, Inc. and Lawrence
Livermore National Security, LLC

effective June 22, 2015

 

This Amendment Three to the License Agreement by and between Lawrence
Livermore National Security, LLC (“LLNS”) and Bionomics Diagnostics, Inc. (“LICENSEE”) is effective
as of the date of execution of this Amendment by the last signing Party. This Amendment and the associated License Agreement are subject
to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No DE-AC52-07NA27344 with the
United States Department of Energy (“DOE”) for the operation of the Lawrence Livermore National Laboratory (“LLNL”).

 

This Amendment Three will modify Article 17 (INSURANCE), Paragraph
17.2 to remove product liability insurance requirement. All other terms and conditions remain the same.

 

Therefore, in consideration of the mutual covenants and obligations
recited herein, LLNS and LICENSEE hereby amend the License Agreement as follows:

 

		1.	ARTICLE 17 (INSURANCE)

 

Delete Paragraph 17.2 in its entirety and replace with the following:

 

		17.2	Prior to obtaining the appropriate government regulatory approvals, LICENSEE may obtain insurance coverage at lower levels,
but the initial minimum levels must be as follows:

 

		17.2.1	Each occurrence coverage of not less than Five Hundred Thousand Dollars ($500,000); and

 

		17.2.2	Personal and Advertising Injury: Coverage of not less than Five Hundred Thousand Dollars ($500,000); and

 

		17.2.3	General Aggregate (Commercial Form only): Coverage of not less than One Million Dollars ($1,000,000).

 

    	17GM0914	 2	TL02679.3 
 Amendment Three

     

    

 

	Bionomics Diagnostics, Inc.,
    a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	Diagnostic
    Kiosk

    Amendment
    Three

 

LLNS and LICENSEE execute this Amendment, in duplicate originals,
by their respective officers who are duly authorized on the day and year that is written.

 

	BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc	 	LAWRENCE LIVERMORE NATIONAL SECURITY, LLC LAWRENCE LIVERMORE NATIONAL LABORATORY
	 	 	 	 	 
	By:	/s/ John Regan	 	By:	/s/ Richard Rankin
	Name:	John Regan	 	Name:	Richard A. Rankin
	Title:	CEO	 	Title:	Director, Innovation and Partnerships Office
	Date Signed:	9/14/2017	 	Date Signed:	09/15/2017
	 	 	 	 	 	 	 

    	17GM0914	 3	TL02679.3 
 Amendment ThreeExhibit 10.9

 

AMENDMENT FOUR

To 

LIMITED EXCLUSIVE

PATENT LICENSE AGREEMENT

 

For

 

DIAGNOSTIC KIOSK 

For Food Safety, Water Quality Monitoring, and

Human/Veterinary Clinical Diagnostics

 

Between

 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

 

and

 

BIONOMICS DIAGNOSTICS, INC.,

a wholly-owned subsidiary of LexaGene Holdings, Inc.

 

LLNL Case No. TL02679.4

 

Lawrence Livermore National Laboratory

Innovation and Partnerships Office

P.O. Box 808, L-795, Livermore, CA 94551

 

September 18, 2019

 

     

     

    

 

	Bionomics Diagnostics, Inc.,
    a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	Diagnostic
    Kiosk

    Amendment
    Four

 

AMENDMENT FOUR 

September 18, 2019

 

to

 

License Agreement - LLNL Case Number TL02679

for Diagnostic Kiosk

between Bionomics Diagnostics, Inc. and Lawrence
Livermore National Security, LLC

effective June 22, 2015

 

This Amendment Four to the License Agreement by and between Lawrence
Livermore National Security, LLC (“LLNS”) and Bionomics Diagnostics, Inc. (“LICENSEE”) is effective
as of the date of execution of this Amendment by the last signing Party. This Amendment and the associated License Agreement are subject
to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No DE-AC52-07NA27344 with the
United States Department of Energy (“DOE”) for the operation of the Lawrence Livermore National Laboratory (“LLNL”).

 

This Amendment Four will modify Exhibit B (RIGHTS GRANTED AND
PERFORMANCE OBLIGATIONS). All other terms and conditions remain the same.

 

Therefore, in consideration of the mutual covenants and obligations
recited herein, LLNS and LICENSEE hereby amend the License Agreement as follows:

 

		1.	Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS), Paragraph B.5 (Performance Obligations)

 

Delete Paragraph B.5 in its entirety and replace with the following:

 

	B.5	Performance Obligations

 

		B.5.1	LICENSEE will complete proof-of-concept prototype by January 31, 2018.

 

		B.5.2	LICENSEE will achieve First Commercial Sale (“FCS”) in the United States by December 31, 2020.

 

		8.5.3	LICENSEE will be granted license by the USDA to sell into veterinary diagnostics markets and receive AOAC certification to
sell into food safety markets in the United States by December 31, 2020.

 

		8.5.4	LICENSEE will achieve cumulative sales of more than Ten Million Dollars ($10,000,000) within three (3) years of FCS.

 

 

    	19GM0918	 1	TL02679.4 
 Amendment Four

     

    

 

	Bionomics Diagnostics, Inc.,
    a wholly-owned subsidiary

    LexaGene Holdings, Inc.

     
	Diagnostic
    Kiosk

    Amendment
    Four

 

		8.5.5	LICENSEE will achieve FDA clearance to perform human clinical diagnostics in the United States by December 31. 2022.

 

		B.5.6	The sales requirements specified above may, by mutual written consent of LICENSEE and LLNS, be amended and/or extended at the
written request of LICENSEE to LLNS. based upon legitimate business reasons specified in reasonable detail in such written request.

 

		8.5.7	The first progress report will be due on February 28, 2016.

 

		B.5.8	LICENSEE will diligently proceed to commercially develop, file relevant regulatory applications for, and attempt to obtain
relevant regulatory commercialization approvals with respect to the manufacturing, marketing, and sale of Licensed Products.

 

LLNS and LICENSEE execute this Amendment, in duplicate originals,
by their respective officers who are duly authorized on the day and year that is written.

 

	BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc	 	LAWRENCE LIVERMORE NATIONAL SECURITY, LLC LAWRENCE LIVERMORE NATIONAL LABORATORY
	By:	/s/ Jack Regan	 	By:	/s/ Richard Rankin
	Name:	Jack Regan	 	Name:	Richard A. Rankin
	Title:	Chief Executive Officer	 	Title:	Director, Innovation and Partnerships Office
	Date Signed:	9/18/2019	 	Date Signed:	9/18/2019
	 	 	 	 	 	 	 

    	19GM0918	 2	TL02679.4 
 Amendment Four

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]